Author

A. Palser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

P. Kellam· 2 shared A. C. Walls· 1 shared A. Liguori· 1 shared A. Schaefer· 1 shared B. Brown· 1 shared B. Fiala· 1 shared B. Groschel· 1 shared C. Chen· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

P. Kellam

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Diverse competitor B cell responses to a germline-targeting priming immunogen in human Ig loci transgenic mice

T. Schiffner, A. Palser, J. G. Jardine, A. Liguori, S. Menis, S. Raemisch, X. Hu, D. W. Kulp, X. Wang, J. K. Diedrich, B. Groschel, O. Kalyuzhniy, R. Tingle, K. Le, E. Georgeson, , W. R. Schief

The paper analyzes B cell responses to a germline-targeting immunogen in human Ig loci transgenic mice, finding diverse non-VRC01-class B cells and competitor B cells recognizing epitopes near the VRC01 epitope.

bioRxiv · Jan 22, 2024 · PreprintImmunology

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

A. C. Walls, B. Fiala, A. Schaefer, S. Wrenn, M. N. Pham, M. Murphy, L. V. Tse, L. Shehata, M. A. O'Connor, C. Chen, M. J. Navarro, M. C. Miranda, D. Pettie, R. Ravichandran, J. C. Kraft, , N. P. King

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

bioRxiv · Aug 11, 2020Immunology